EP Patent

EP3318276A1 — Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers

Assigned to Janssen Biotech Inc · Expires 2018-05-09 · 8y expired

What this patent protects

The present invention relates to a combination treatment for hematological cancers. More specifically, a combination of a telomerase inhibitor and a Bcl-2 inhibitor are useful in treating hematological cancers, including AML.

USPTO Abstract

The present invention relates to a combination treatment for hematological cancers. More specifically, a combination of a telomerase inhibitor and a Bcl-2 inhibitor are useful in treating hematological cancers, including AML.

Drugs covered by this patent

Patent Metadata

Patent number
EP3318276A1
Jurisdiction
EP
Classification
—
Expires
2018-05-09
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Biotech Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.